Evidence map›Paper›PMID 39774706›Full record

ReviewArchives of gynecology and obstetrics2025

Hyperandrogenism in polycystic ovary syndrome and adrenal hyperplasia: finding differences to make a specific diagnosis.

Vittorio Unfer, Elisa Lepore, Gianpiero Forte, Imela Hernández Marín, Artur Wdowiak, Lali Pkhaladze

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vittorio UnferUniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy. vunfer@gmail.com.ORCID 0000-0002-1805-3181
Elisa LeporeR&D Department, Lo.Li Pharma, Rome, Italy.ORCID 0009-0004-3610-2145
Gianpiero ForteR&D Department, Lo.Li Pharma, Rome, Italy.ORCID 0000-0003-4720-4054
Imela Hernández MarínThe Experts Group On Inositol in Basic and Clinical Research and On PCOS (EGOI-PCOS), Rome, Italy.
Artur WdowiakThe Experts Group On Inositol in Basic and Clinical Research and On PCOS (EGOI-PCOS), Rome, Italy.ORCID 0000-0002-7011-2345
Lali PkhaladzeThe Experts Group On Inositol in Basic and Clinical Research and On PCOS (EGOI-PCOS), Rome, Italy.ORCID 0000-0003-4690-9140

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePolycystic Ovary Syndrome (PCOS) and Adrenal hyperplasia (CAH) are two pathologic conditions sharing several clinical features (hirsutism, acne, polycystic ovary morphology, metabolic alterations, ovulatory dysfunctions) and especially hyperandrogenism as a common clinical hallmark. Therefore, making a differential diagnosis of the two conditions still remains a great medical challenge.

methodsIn particular, the comparison discussed in this review referred to non-classical form of adrenal hyperplasia (NCAH), which regards the adult population, and the Endocrine Metabolic Syndrome (EMS), following the new set of PCOS diagnostic criteria proposed by the Experts Group on Inositol and Clinical Research, and on PCOS (EGOI-PCOS). To support this review, a literature search was conducted using PubMed, Google Scholar and Web of Science, supplemented by articles known to the authors. Keywords included: polycystic ovary syndrome, non-classical adrenal hyperplasia, hyperandrogenism, and 17-Hydroxyprogesterone.

resultsConsidering the different pathophysiology of the two conditions, the recommended strategy to differentiate diagnosis is testing the blood values of 17-hydroxyprogesterone (17-OHP) in fertile aged women with suspicious hyperandrogenism. Basal values of 17-OHP higher than 2 ng/mL likely indicate NCAH, while values lower than 2 ng/mL exclude the diagnosis of NCAH; in case of borderline values stimulation test with adrenocorticotropic hormone may eventually confirm the diagnosis.

conclusionThis review contributes to make the differential diagnosis between hyperandrogenic PCOS and NCAH clearer, thus also aiming to achieve tailored therapeutic approaches for patients with hyperandrogenism.

Indexed as

Adrenal Hyperplasia, CongenitalHyperandrogenismPolycystic Ovary Syndrome17-alpha-HydroxyprogesteroneAdultDiagnosis, DifferentialFemaleHumansMetabolic Syndrome17-alpha-Hydroxyprogesterone17-OHPAdrenal hyperplasiaDifferential diagnosisEGOI-PCOS criteriaNCAHPCOS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.